心力衰竭和冠状动脉疾病对勃起功能障碍的影响:一项两样本的门德尔随机化研究
Kaiyang Shao1, Weikang Chen2, Yaling Li1
1The Second Affiliated Hospital of Zhejiang University School of Medicine, 88 Jiefang Road,Shangcheng District Hangzhou, 310009, Hangzhou, Zhejiang, China.
BMC urology
|October 13, 2023
概括
这项研究在欧洲人群中没有发现心力衰竭 (HF) 或冠心病 (CAD) 与勃起功能障碍 (ED) 之间的因果关系. 需要进一步的研究才能充分理解这些情况及其潜在的联系.
科学领域:
- 心血管健康 心血管健康
- 男人的健康 男人的健康
- 遗传流行病学遗传流行病学
背景情况:
- 作为勃起功能障碍 (ED) 的风险因素,心力衰竭 (HF) 和冠心病 (CAD) 之间的关系尚不清楚.
- 现有的研究缺乏关于这些心血管疾病和ED之间的因果关系的最终结论.
研究的目的:
- 调查基因预测心力衰竭 (HF) 和冠心病 (CAD) 以及勃起功能障碍 (ED) 的发生率之间的潜在因果关系.
- 利用孟德尔随机化 (MR) 分析来评估HF和CAD在ED发展中的病因作用.
主要方法:
- 孟德尔随机化 (MR) 分析是使用来自MRC IEU Open GWAS数据库的单核酸多态 (SNP) 进行的.
- 逆方差加权 (IVW) 方法是主要分析技术,敏感性分析包括科克兰的q测试,MR-Egger回归和MR-PRESSO以确保稳定性.
主要成果:
- 该研究发现,基因预测心力衰竭 (HF) 和勃起功能障碍 (ED) (OR = 1.17,p = 0.074) 之间没有统计学上显著的因果关系.
- 同样,在冠状动脉心脏病 (CAD) 和勃起功能障碍 (ED) (OR = 1.08,p = 0.068) 之间也没有观察到显著的因果关系.
- 灵敏度分析证实,没有横向的形变异,支持了主要的发现.
结论:
- 这项门德尔随机化研究没有在欧洲人口中建立心力衰竭 (HF) 或冠心病 (CAD) 和勃起功能障碍 (ED) 之间的因果关系.
- 需要进一步进行全面的研究,以阐明心血管疾病和ED之间的复杂相互作用.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
441
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
441
01:27Heart Failure I: Introduction
14
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
14
01:30Heart Failure V: Medical Management
10
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
10
01:29Heart Failure II: Pathophysiology
14
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
14
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:22Heart Failure Drugs: β-Blockers
346
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
346